A bright commercial future for off-the-shelf NK cell therapy
Jan Spanholtz(AIMM Therapeutics (Netherlands)), Volker Huppert(Miltenyi Biotec (Germany)), Troels Jordansen
Cited by 0
Related Papers
Clinical-Grade Generation of Active NK Cells from Cord Blood Hematopoietic Progenitor Cells for Immunotherapy Using a Closed-System Culture Process
|PLoS ONE|2011|239
Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients
|Clinical Cancer Research|2017|211
The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments
|Frontiers in Immunology|2017|197
High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy
|PLoS ONE|2010|183
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies
|Journal of Hematology & Oncology|2022|178